Regeneron falls after appeals court ruling in Eylea case (update)
Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).
BMO says Eylea court decision ‘modest negative’ for Regeneron
BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...
Eylea biosimilar injunction denial ‘negative’ for Regeneron, says UBS
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Regeneron stock dips as court denies Eylea patent stay
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
Endpoints News2d
Fed­er­al Cir­cuit rul­ing al­lows Am­gen's Eylea biosim­i­lar to stay on the mar­ket
The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...
Insider Monkey5d
11 Best Pharma Stocks to Buy According to Hedge Funds
Eylea, which Regeneron Pharmaceuticals ... ranks tenth on our list of the 11 best pharma stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers ...
news.bloomberglaw2d
Amgen Keeps Win Over Regeneron Bid to Block Eylea Biosimilar (1)
Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit. Amgen’s biosimilar formulation ...